Antacids may leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
Interventions showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
The review found no eligible studies for this question.
Antacids showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
The review found no eligible studies for this question.
Antacids showed no clear difference in number of participants requiring blood transfusions compared with placebo or no prophylaxis (low certainty).
The review found no eligible studies for this question.
Sucralfate probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
Sucralfate showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
Sucralfate showed no clear difference in number of participants requiring blood transfusion compared with placebo or no prophylaxis (low certainty).
Interventions showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
The review found no eligible studies for this question.
H2 receptor antagonists may leads to higher clinically important upper GI bleeding compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with proton pump inhibitors (moderate certainty).
The review found no eligible studies for this question.